Accelerating Precision Oncology with Innovative NAM Platforms

The future of cancer therapy lies in precision—understanding each patient’s unique biology to design treatments that truly work. At NAMina Bio, our mission is to accelerate that future by reimagining how cancer research is conducted. We are building a new foundation for precision oncology through New Approach Methodologies (NAMs) that merge innovation with compassion, advancing discovery while minimizing reliance on animal testing.

Our aim is to create a next-generation drug discovery platform that unites patient-derived organoids, organ-on-a-chip systems developed in partnership with Revivocell, and AI-driven predictive analytics powered by KolateAI. This integrated system will enable high-throughput, human-relevant screening of drug candidates and natural compounds—allowing us to predict therapeutic responses with far greater accuracy and speed than traditional methods.

By developing multiscale human avatars, NAMina Bio seeks to capture the complexity of cancer across molecular, cellular, and microenvironmental levels. These models will help researchers uncover how tumors evolve, resist treatment, and interact with their surroundings—bridging the translational gap that too often separates laboratory findings from clinical reality.

Our long-term vision is to empower precision oncology with NAMs—contributing not only to scientific progress but also to regulatory advancement and ethical reform. By helping to redefine testing standards in line with the FDA Modernization Act 2.0, we aim to make personalized, human-based research both accessible and sustainable.

At its heart, NAMina Bio stands for a smarter, more humane, and more effective approach to cancer innovation. We envision a world where every therapy is informed by real human biology, where compassion meets technology, and where precision medicine and ethical science converge to transform the lives of patients worldwide.